PIA
MGNX icon

Piedmont Investment Advisors’s MacroGenics MGNX Stock Holding History

Piedmont Investment Advisors’s Portfolio MGNX Stock Details MGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-681
Closed -$14K – 1767
2018
Q2 		$14K Buy
+681
New +$15.3K ﹤0.01% 1714

Other funds holding MGNX

O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return

Piedmont Investment Advisors's MGNX Position: Q3 2018 in Review

Piedmont Investment Advisors sold out of MacroGenics (MGNX) in Q3 2018, closing a stake of 681 shares — an estimated $14K sold.

Piedmont Investment Advisors first reported a position in MGNX in Q2 2018 and held it in 1 quarter. The position peaked at $14K in Q2 2018. 130 funds tracked by Wall St. Rank hold MGNX as of Q3 2018.

  • Piedmont Investment Advisors reported no remaining MacroGenics position as of Q3 2018 after selling out during the quarter.
  • Piedmont Investment Advisors sold 681 MacroGenics shares in Q3 2018, an estimated $14K.
  • Piedmont Investment Advisors first reported a position in MacroGenics in Q2 2018 and held it in 1 quarter.
  • Piedmont Investment Advisors's MacroGenics position peaked at $14K in Q2 2018.
  • 130 funds tracked by Wall St. Rank held MacroGenics as of Q3 2018.

Based on Piedmont Investment Advisors's 13F filing for Q3 2018, filed 8 Nov 2018.